trial

SPECT Study With SB-773812 In Schizophrenic Patients

NCTId NCT00269035
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 95 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2007-05-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
95 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
—
Start
2005-06-21
Primary completion
2007-05-26
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SB773812Risperidone

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

6 total
Barcelona, SpainBarcelona, SpainBarcelona, SpainMataro (Barcelona), SpainSant Boi de Llobregat, SpainVic (Barcelona), Spain

Facts & assertions

4 sourced
Enrollment
95
Phase
PHASE1
Primary Completion Date
2007-05-26
Status
COMPLETED
relationships
The graph out of here
drug
SB773812
drug
Risperidone
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication